Filter posts

#BIOCEO19: We’re Out of Time to Address the Dire Market Failures in Antimicrobial Resistance

Here’s a statistic you might not have known: an estimated 700,000 people die each year …

Venture Creation is in Vogue

In the biotech industry, it’s common for a company to raise billions of dollars and …

Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical ...

In his State of the Union address, President Trump called on Congress to “do more” …

#BIOCEO19: Navigating Payers’ Expectations for Value-Based Agreements

Value-based agreements are becoming increasingly important in the biopharmaceutical reimbursement space, particularly as new advanced …

Market Outlook—Leveraging Market Corrections for M&A or IPOs

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year …

#BIOCEO19 Kicks Off in NYC

Pharmaceutical innovation is not slowing down. Last year the FDA approved a total of 59 …

Using Decision Science for Negotiations: Getting to Win-Win

New medicines often progress from idea to regulatory approval through collaborative licensing agreements or acquisition.  …

Investors lining up for BIO CEO & Investor Conference

The past year has been a transformative one for the life sciences. Despite being faced …

Meet Opiant’s Roger Crystal, Fireside Chat Speaker at #BIOCEO19

When pop star Demi Lovato experienced an apparent opioid-related overdose last summer, reports stated that …